MRD and Disease Monitoring
Knowing how well you are responding to any therapy is going to help guide whether it should be continued, changed, augmented, or stopped. There are lab tests and sometimes imaging and physical examinations that can help. One of the newest tools is testing for MRD, or measurable (AKA minimal) residual disease, which can detect very low levels of CLL in the blood or in the bone marrow, as explained in this basic article by Dr. Brian Koffman. This can help inform optimal management.
The second half of this article deals with how we traditionally measure response to any CLL/SLL therapy, not only in a clinical trial, but in any and all settings. How we assess responses using complete response (CR), partial response (PR), stable and progressive disease, and/or by using MRD is evolving quickly and will vary with the individual’s clinical circumstance.
CLL Society Webinar Archive – MRD: What Should it Mean to Me?
MRD (minimal or measurable residual disease) is important to understand, not just in clinical trials, but increasingly in guiding real world CLL decisions you may need to make with your doctors. Join Dr. Anthony Mato as he discusses testing and research on MRD and its growing role in CLL management along with Dr. Brian Koffman. Watch Now.
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
LIST OF CLL DOCTORS
NORMAL LAB VALUES
TESTING AND IMAGING
ASK THE EXPERTS
ABBREVIATIONS AND GLOSSARY
FREE CLL EXPERT OPINION